On January 12th local time, Merck announced that the US Food and Drug Administration (FDA) has approved the use of Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemotherapy (CRT) for the treatment of stage III-IVA cervical cancer patients defined by the International Federation of Obstetrics and Gynecology (FIGO) 2014.